AAV9-ABCD1 Vector Production and Intrathecal Delivery for X-ALD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current delivery systems for treating X-linked adrenoleukodystrophy (X-ALD) face challenges such as cardiac toxicity due to transgene overexpression when using intravenous delivery of adeno-associated virus (AAV) vectors encoding the ABCD1 gene, necessitating a method to achieve non-toxic levels of ABCD1 expression in patients.
Innovation Solution
Increasing AAV9 vector titers in producer cells by incubating them with a nucleic acid sequence complementary to ABCD1 mRNA, such as siRNA, to decrease ABCD1 mRNA expression and enhance vector yield, followed by intrathecal administration of the purified AAV9-ABCD1 vector using an osmotic pump to minimize ABCD1 expression in peripheral organs and maximize it in the central nervous system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravenous delivery of AAV vectors encoding ABCD1 is used to treat X-ALD, then ABCD1 gene delivery to the central nervous system is achieved, but cardiac toxicity occurs due to transgene overexpression in peripheral organs
Solution Approach 1:
The invention segments the delivery approach by using intrathecal administration to target the central nervous system specifically, while using siRNA to segmentally suppress ABCD1 expression in peripheral organs. This spatial segmentation prevents cardiac toxicity while maintaining CNS treatment efficacy.
Solution Approach 2:
The invention applies preliminary anti-action by co-administering siRNA that targets ABCD1 mRNA to prevent transgene overexpression before it can cause cardiac toxicity. The siRNA is introduced simultaneously or prior to the AAV vector to preemptively block harmful expression in peripheral organs.
2Object-affected harmful factors
If intrathecal administration is used to deliver AAV-ABCD1 vector, then ABCD1 expression in peripheral organs is minimized, but the vector yield from producer cells must be increased to ensure adequate dosing
Solution Approach 1:
The invention applies preliminary anti-action in the production phase by transfecting producer cells with siRNA targeting ABCD1 mRNA before AAV vector production. This preemptively reduces endogenous ABCD1 expression that would otherwise compete with vector production or cause toxicity, thereby increasing vector yield while maintaining the ability to minimize peripheral expression upon administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach results in a significant increase in AAV9-ABCD1 vector yield and reduces ABCD1 expression in peripheral organs, thereby minimizing toxicity while achieving effective ABCD1 expression in the central nervous system, leading to improved treatment outcomes for X-ALD.
Implementation Method 1
incubating them with a nucleic acid sequence complementary to ABCD1 mRNA, such as siRNA, to decrease ABCD1 mRNA expression
Implementation Method 2
followed by intrathecal administration of the purified AAV9-ABCD1 vector using an osmotic pump
Data Source
AI summary
Methods of the invention encompass delivery of nucleic acid sequences encoding ABCD1 for the treatment of X-linked Adrenoleukodystrophy (X-ALD), e.g., for Adrenomyeloneuropathy (AMN).